ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / LXRX
IMMX (29) ABUS (18) ANL (46) OLMA (29) ⌘ Pro Terminal β†’

Lexicon Pharmaceuticals Inc. (LXRX) β€” RQD Stock Rating Cockpit

$1.44 +1.41% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.44

Lexicon Pharmaceuticals Inc. (LXRX) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $631.8M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LXRX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is LXRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.44 (+1.41% 1D, market cap $631.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does LXRX compare to IMMX and ABUS in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $645.3M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LXRX?
β–Ό

Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.44 (+0.06%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (26/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510026
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (4)Whales (3)SEC (11)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.6% Base Target
$3 Bull$1 Base$1 Bear
πŸ“¬ FREE LXRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for LXRX)Realized 20D OHLCV Swing Band: Β±11%
Deterministic 5-Pillar Attribution (26/100 Composite)
πŸ” WHY LXRX SCORES 26/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (42% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Macro Regime Fit+5/20 pts (19% of score)

FRED Regime Γ— Technicals: 22% of 52W Range β€’ RSI-14 at 32.6 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
34
Grade E$1.61-1.9% Next Q
Q2 (-2Q)
31
Grade E$1.58-6.3% Next Q
Q3 (-1Q)
29
Grade E$1.48-2.7% Next Q
Current
26
Grade E$1.44-10.5% Hist 90D Ξ±
Trajectory: E (34) β†’ E (26)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a LXRX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While LXRX currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.51) forces dealer call-delta covering toward $2.81.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LXRXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œLXRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
32.630 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE22% OF RANGE
L: $1$1.44H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on LXRX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-31.5% ROIC with 96.0% gross margin and -10.30% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (18)

6/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like LXRX
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LXRX)

  • βœ“Walkthrough of LXRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
LXRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.00%β–Ό DESCENDING CHANNEL
2026-11-03O $1.48H $1.48L $1.42C $1.44VOL 2.44M
RES: $2.12SUP: $1.29SMA50: $1.85SMA200: $1.89
$2.77$2.39$2.01$1.63$1.25RES $2.12SUP $1.29$1.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LXRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ LXRX Butterfly Map β†’ + Track LXRX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +729.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LXRX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for LXRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LXRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LXRX)

Health Care Rank #904 of 1015 βš”οΈ IMMX vs LXRX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (LXRX vs. IMMX, ABUS, ANL, OLMA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lexicon Pharmaceuticals Inc. (LXRX) ranks #904 by composite RQD confidence (26/100, grade E) and #408 by equity capitalization ($631.8M). Within this direct 5-issuer industry benchmark cohort, LXRX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with LXRX at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LXRX ACTIVE
Lexicon Pharmaceuticals Inc.
E 26/100 β€” 96.0% -31.5% +1.41% $631.8M Benchmark Subject
IMMX
Immix Biopharma Inc.
E 29/100 β€” β€” -35.0% -5.47% $636.7M /immx-vs-lxrx β†’
ABUS
Arbutus Biopharma Corporation
E 18/100 β€” β€” -35.0% -4.99% $645.3M /abus-vs-lxrx β†’
ANL
Adlai Nortye Group Ltd.
D 46/100 β€” β€” β€” -1.88% $615.0M /anl-vs-lxrx β†’
OLMA
Olema Pharmaceuticals Inc.
E 29/100 β€” β€” -32.8% +1.00% $612.5M /olma-vs-lxrx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001062822 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported GAAP revenue of $49.8M (+729.9% vs. FY2024 revenue of $6.0M , and +4386.8% cumulative change since FY2023) , GAAP net income of -$50.3M, operating cash flow of -$67.9M, and free cash flow of -$67.9M (+62.3% YoY). On the balance sheet, LXRX closed FY2025 with $185.0M in total assets against $49.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $49.8M -$50.3M -$67.9M -$67.9M $185.0M $49.4M
FY2024 (FY) 2024-12-31 $6.0M -$200.4M -$178.8M -$179.8M $298.4M $100.3M
FY2023 (FY) 2023-12-31 $1.1M -$177.1M -$161.9M -$161.9M β€” β€”

3. LXRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LXRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.44 (+1.41% 1D, market cap $631.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does LXRX compare to IMMX and ABUS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $645.3M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LXRX?

Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LXRX trading relative to its 50-day, 200-day, and 52-week technical levels?

LXRX last traded at $1.44 (+1.41% on volume of 2,020,779 shares), positioning the stock -22.16% below its 50-day simple moving average ($1.85) and -23.81% below its 200-day simple moving average ($1.89). Across its 52-week range of $1.10 to $2.68, LXRX sits at the 21.5% percentile with a 14-day RSI of 32.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.0% ($1.28 to $1.60).

Direct Sub-Reports: LXRX RQD Cockpit LXRX 12M Forecast LXRX Earnings & Move LXRX Dividends & DRIP LXRX Insiders & 13F LXRX Whale Options LXRX Profit Sankey LXRX News & Why
ROARABLE RATING BRIEF β€’ RQD 26/100 (E) βœ“ SEC XBRL & RQD VERIFIED

LXRX β€” Lexicon Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lexicon Pharmaceuticals Inc. (LXRX) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.44 (+1.41% 1D, market capitalization $631.8M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -31.5%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of -10.30%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of 0.46x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lexicon Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported $49.8M in annual revenue (up from $6.0M in FY2024, +729.9% YoY) and -$50.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.1M revenue, -$177.1M net income) through FY2025, LXRX scaled operating cash flow to -$67.9M and free cash flow to -$67.9M, backed by $185.0M in total assets against $49.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.30% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.10 – $2.68 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The main 2nd-order channel visible in the data is liquidity sensitivity: the macro signal implies that LXRX's price responds to shifts in net liquidity, so a tightening of liquidity conditions, as reflected in the Fed, TGA, and RRP components, would be a ripple risk. Investors should also watch the high-yield spread, which the signal cites at +2 bps, as an indicator of financing conditions for cash-consuming issuers.

  • Key Question #1: Can LXRX sustain or expand its -60.0% operating margin and -31.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $49.8M and free cash flow of -$67.9M, how will capital allocation balance growth reinvestment against $49.4M in total debt?
  • Key Question #3: How sensitive is LXRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LXRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lexicon Pharmaceuticals Inc. (LXRX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to LXRX Debate Forum (3) ↓
🟑 MARKET WIRE Yahoo β€’ 11d ago
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial o

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LXRX Bull vs. Bear Conversation Board β€” What's Your Call at $1.44?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LXRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LXRX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $1.79 (+26.1%)
πŸ“Œ Pinned Debate

The Butterfly liquidity signal scores 92/100 as a Macro Tailwind with a 2.97x Net Liquidity beta, and revenue grew from $1.1M in FY 202

Long LXRX at $1.42 targeting $1.79. The Butterfly liquidity signal scores 92/100 as a Macro Tailwind with a 2.97x Net Liquidity beta, and revenue grew from $1.1M in FY 2023 to $49.8M in FY 2025.. Institutional whale score is 3/20 and the risk/reward vs. the $1.10 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd πŸ‚ BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (96.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER β€’ Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.09 (-23.2%)
Spot @ $1.42

ROIC is -31.5%, FCF yield is -10.3%, and the Fundamental Cash Engine pillar scores only 4 of 20 on the RQD rating.

I respect the product at Lexicon Pharmaceuticals Inc., but the stock at $1.42 is a different story. ROIC is -31.5%, FCF yield is -10.3%, and the Fundamental Cash Engine pillar scores only 4 of 20 on the RQD rating.. FCF yield is -10.3% and RQD sits at 26/100 (E) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE